WuXi Biologics Starts Building Chengdu Manufacturing Plant, its 12th Globally
publication date: May 16, 2019
WuXi Biologics, a China biologics CRO/CMO, has begun construction of a new 1.3 million square foot integrated manufacturing center for innovative biologics in Chengdu, one of the largest cities in Southwest China. The facility will be WuXi Biologics' 12th drug substance manufacturing facility. Bu 2022, WuXi plans to have a total production capacity of 220,000 liters, with facilities around the world, including China, Ireland, Singapore and US. Initially, the Changdu facility will have a bioreactor capacity of 48,000 liters. More details....
Stock Symbol: (HK: 2269)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.